Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets

Key Takeaways

• Veristat adds full regulatory support for Chinese firms in Europe
• Over 68 INDs and 18 marketing applications submitted 2020‑25
• Chinese-origin drugs projected $34B revenue by 2030
• Service includes gap analysis, dossier development, agency negotiations
• Enables market entry without local legal entity

Summary

Veristat announced an expansion of its regulatory and clinical‑trial services aimed at Chinese pharmaceutical and medical‑device companies seeking faster entry into European markets, as well as the United Kingdom, Switzerland, the United States, Canada and Australia. The CRO highlighted recent successes with Hansoh Pharma and CStone Pharmaceuticals, noting its role in preparing and filing Marketing Authorization Applications and New Drug Applications based largely on foreign data. Between 2020 and 2025 Veristat submitted 68 INDs, 10 FDA marketing applications and eight EMA/MHRA/Swissmedic filings. The move aligns with the surge of Chinese‑origin drug candidates, which Morgan Stanley forecasts could generate $34 billion in revenue by 2030.

Pulse Analysis

China’s drug discovery engine is rapidly maturing, with nearly half of all new molecular entities in human trials now originating from Chinese labs. This pipeline shift is reshaping global R&D strategies, but the lack of local regulatory expertise often stalls cross‑border commercialization. Companies that can bridge the gap between domestic approval and foreign market requirements stand to capture a sizable share of the projected $34 billion revenue stream by 2030, making regulatory navigation a critical competitive advantage.

Veristat leverages three decades of CRO experience to offer a turnkey solution for Chinese sponsors. Its multidisciplinary team conducts rigorous gap analyses, crafts region‑specific dossiers, and can act as the official applicant, eliminating the need for a physical presence in target markets. The firm’s track record—68 IND submissions, 10 FDA applications, and eight EMA/MHRA/Swissmedic filings between 2020 and 2025—demonstrates an ability to translate foreign clinical data into approvals across the EU, UK, US, Canada, and Australia. By handling complex therapies such as cell and gene treatments, Veristat positions itself as a strategic partner for advanced‑medicine developers.

The broader industry impact is twofold. First, faster market entry accelerates patient access to innovative therapies, especially in rare and oncology indications where time‑to‑treatment is critical. Second, investors gain confidence in Chinese biotech pipelines when a proven regulatory conduit exists, potentially driving higher valuations and cross‑border licensing deals. As Veristat showcases its capabilities at BIO China and CMAC, the CRO is likely to become a pivotal bridge in the evolving global pharmaceutical ecosystem.